Par Nijhawan
Company: Edesa Biotech
Job title: Chief Executive Officer
Seminars:
Panel Discussion: Considering Early Endpoints in Clinical Trials to Benchmark ARDS Therapeutic Progress & Confidently Prove Proof of Concept 9:15 am
day: Day One
Evaluating Previous ARDS Preclinical & Clinical Trial Designs to Assess the Optimum Path to Take for Future Studies: TLR4 Inhibitors with a Monoclonal Antibody to Treat ARDS 8:25 am
Highlighting the mechanism of action of EB05, a TLR4 inhibitor Reviewing the components of preclinical study designs which allowed or inhibited progression to the clinic Delving into past clinical trial designs to enable the success of current and future clinical trialsRead more
day: Day One